Navigation Links
A common cholesterol drug fights cataracts, too
Date:2/9/2010

Statins, a class of drugs used to lower cholesterol levels, have been successfully fighting heart disease for years. A new study from Tel Aviv University has now found that the same drugs cut the risks of cataracts in men by almost 40%.

"Doctors have known for some time that there is some sort of preventative effect that statins have against cataracts," says Dr. Gabriel Chodick of the Department of Epidemiology and Preventive Medicine at the Sackler Faculty of Medicine at Tel Aviv University, who led the study. "It seems that they protect the eye from inflammation and ocular nerve cells from a process of oxidization. But ours is the first study to show such a strong association in such a large population."

The study covered over 180,000 patients between the years of 1998 and 2007 and was published in the February 2010 issue of the Annals of Epidemiology.

From the heart to the head

Dr. Chodick and his colleague Dr. Varda Shalev found that men aged 45 to 54 who took the statins daily to lower their cholesterol levels also lowered their chances of developing cataracts by 38%. For women of about the same age, the risk for cataracts was also cut dramatically, by about 18%.

Dr. Chodick has been studying the health benefits of statins for years. One of his recent studies, featured as part of a Time magazine cover story, showed that statins can reduce a person's chance of dying from all combined diseases and conditions by 40% something in the medical community called "all-cause mortality."

"People who persistently take statins have tremendously reduced chances of premature death by disease. We began to think that statins, which are proven to prevent cardiovascular disease, may do other good things in the body as well. We started investigating cataracts to show statins' effects in a more statistical manner," says Dr. Chodick.

A statin a day

"Statins are not being taken consistently by patients, and only about 10% of those who get these prescriptions actually end up taking them. Once you start, it's important to continue taking them to avoid cardiovascular problems," Dr. Chodick warns. "But now we have even more good reasons to keep taking statins ― like an apple a day. People who begin taking them in their 40s to early 60s can reap a number of benefits, including better protection against cataracts."

A cataract is a type of clouding that develops in the lens of the eye, leading to varying degrees of sight impairment. It typically progresses slowly so that the sufferer may not even be aware of the problem. If left untreated, a cataract can lead to blindness. In the U.S., cataracts affect about 60% of both men and women over the age of 60. About 1.5 million cataract surgeries are performed in the U.S. each year, and visual disabilities associated with cataracts lead to over 8 million physician office visits a year.

"We believe that the regular use of statins for men and women under the age of 75 can significantly protect them against cataracts," Dr. Chodick concludes. Whether people who are not at risk for heart attacks should take them as a cataract preventative alone has not been determined. But before long we may be taking a daily statin pill along with our daily vitamin tablet, Dr. Chodick believes.


'/>"/>

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University
Source:Eurekalert  

Related medicine news :

1. Adapting to clogged airways makes common pathogen resist powerful drugs
2. Metabolite common among cancers
3. Nutrition Management Services Company Announces Decision to Deregister its Class A Common Stock
4. Cracking the code on common wrist injury
5. Murtha Gallbladder Removal Complications Underscore Risk of Common Surgery
6. Sinovac Announces Closing of Common Share Offering
7. Parkinsons More Common in Northeast, Midwest
8. Skipping Insulin May Not Be Uncommon
9. Common antidepressant drugs linked to lactation difficulties in moms
10. Complications common, often linked to trauma in children receiving cochlear implants
11. Deadly Choking Game Still Common Among Kids
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A common cholesterol drug fights cataracts, too
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: